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Background: Chronic obstructive pulmonary disease (COPD) continues to increase worldwide. 
The objective of this study was to determine the prevalence of COPD in Lebanese adults.
Methods: A cross-sectional study was carried out using a multistage cluster sample from 
all over Lebanon. Residents aged 40 years and over were enrolled. Subjects underwent 
baseline   spirometry and answered a questionnaire. After an albuterol + ipratropium bromide 
  bronchodilator, a posttest was performed.
Results: Of 2201 individuals, only 33.3% had never smoked. The prevalence of COPD by the 
Global Initiative for Chronic Obstructive Lung Disease definition, was 9.7% (95% confidence 
interval [CI]: 8.5%–10.9%). According to the 5% lower limit of normal definition of COPD, 
the prevalence was 12.5% (95% CI: 11.2%–13.9%). A total of 20.2% were already diagnosed 
by a physician. No differences in symptoms across stages of COPD were found, but there 
was a significant trend for a higher number of visits to the emergency room and to the doctor 
(P , 0.001), and a higher number of hospitalizations (P , 0.001). Older individuals had an 
increased risk of COPD (adjusted odds ratio [ORa] = 1.05); so did “ever” cigarette smokers 
(ORa = 4.88) and water-pipe smokers (ORa = 2.53).
Conclusion: This is the first epidemiological study in Lebanon that determined COPD preva-
lence and the link with water-pipe smoking.
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Introduction
Chronic obstructive pulmonary disease (COPD) is projected to rank third as a cause 
of mortality by 2020,1 and its burden is increasing worldwide. Early diagnosis of this 
disease is a challenge for the coming years.1,2 Risk factors and the clinical context 
are important for a positive diagnosis, but pulmonary function tests are needed for 
confirmation.1–3 Defining COPD on the flow volume curve relies on one criterion: the 
post-bronchodilator forced expiratory volume at 1 second (FEV1)/forced vital capac-
ity (FVC) ratio being less than 70%.1,3,4 New insight has been put on the limitations 
of such a diagnostic criterion,4–6 and some have discussed the value of the 5% lower 
limit of normal (LLN) for more accurate COPD diagnosis.4,7
Despite the background outlined above, and the controversy about the changing preva-
lence of COPD worldwide,8,9 data are still lacking in Lebanon. It is noteworthy that while 
a smoking ban was finally brought in to public places in Lebanon in August this year, this 
study would be the first national cross-sectional one with the objective of determining 
the prevalence of COPD in the Lebanese adult population. It can therefore be a starting 
point for building health policies for smoking-related diseases in this country.
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What was already known on this subject?
No data were previously available about COPD in Lebanon. 
This is the first national study on adults aged 40 years and 
over, with no exclusion criteria, revealing a high prevalence 
of COPD. It highlights also in this smoker population that 
80% of the cases are not recognized and not diagnosed as 
COPD. It reveals a robust link between water-pipe smoking 
and COPD.
What does this study add?
Raising awareness among health care professionals and 
the public about COPD is fundamental. This study will 
encourage early diagnosis of COPD, early treatment, and 
secondary and primary prevention. This will contribute to 
the application of the Framework Convention on Tobacco 
Control about the antismoking policy signed by Lebanon. It 
will help to demystify the myth about the nonharmful effect 
of water-pipe smoking.
Methods
Study design and population
A cross-sectional study was carried out between October 
2009 and September 2010, using a multistage cluster sample 
from all over Lebanon. Lebanese residents aged 40 years and 
over were enrolled in the study, with no exclusion criteria. 
The reason for choosing 40 years as the lower cutoff age 
was to reduce the probability of asthma being the prevalent 
disease in a younger sample. The total number of males in 
the study population was 614,564, while the total number 
of females was 653,751.10 The Institutional Review Board 
of the Lebanese University stated that an approval was not 
necessary since the study was an observational one and not 
experimental, clinical, or interventional. No approval number 
was allocated for this statement.
Procedure
From the list of circumscriptions in Lebanon (villages, towns, 
and cities),11 100 were randomly selected through a repre-
sentative of local authorities; randomization was   performed 
using a software program. Individuals aged 40 years and 
over were then randomly chosen to be interviewed from a 
provided list of dwelling households. After an oral informed 
consent, subjects underwent baseline spirometry (Micro Lab; 
Micro Medical Ltd, Kent, UK) by a trained technician and 
answered a questionnaire. Since albuterol or ipratropium are 
recommended bronchodilators to be used for spirometric 
reversibility testing performed in a laboratory,12 with no 
clear consensus whether to use both of them   simultaneously 
or   consecutively, post-bronchodilator spirometry was 
performed 30 minutes after the inhalation of two puffs 
of combined ipratropium bromide (18 µg/  actuation) and 
albuterol sulfate (103 µg/actuation) (Combivent®;   Boehringer 
Ingelheim, Ingelheim, Germany) in a pressurized metered-
dose aerosol unit. The best result out of three trials was taken 
into account.
The questionnaire of the American Thoracic Society for 
evaluation of chronic pulmonary disease13 and the   Medical 
Research Council (MRC) score to evaluate dyspnea14 
were used. Questionnaires were translated into Arabic by 
an independent translator and checked by investigators; 
a back translation by another translator was done to ensure 
lack of discrepancy between English and Arabic versions. 
The questionnaire was then pretested in a pilot sample 
of 20 individuals for finalization of details. Moreover, 
questions about weight, height, and a diagnosed cardiac 
problem were also asked. In addition to health questions, 
data were collected concerning sociodemographic char-
acteristics (eg, age, sex, education, marital status, region 
of dwelling) and cigarette and water-pipe smoking history 
(current-, previous-, or never-smokers). Cigarette smoking 
was defined as smoking more than one pack in a lifetime, 
while current water-pipe smoking was defined as a positive 
answer to the question “do you regularly smoke water-
pipe?”, and previous water-pipe smoking was defined as a 
positive answer to the question “were you a regular smoker 
of water-pipe?”
Sample size calculation
A minimal simple random sample size of n = 1015 was 
required to measure the prevalence of COPD in Lebanon, 
in an adult population aged 40 years and over. According 
to other studies in the world that show a variation of COPD 
prevalence around 9%–12%,15,16 a worst acceptable result 
of ±2% difference with the abovementioned prevalence 
and a 95% confidence interval (CI) was taken into account 
and added to the multistage sampling design, thus giving a 
minimal sample size of 2030 individuals.
Statistical analysis
SPSS Statistics (IBM Corporation, Somers, NY) software, 
version 17.0, was used to enter and analyze data. Weighting 
was performed according to the numbers published by the 
Lebanese Ministry of Social Affairs and the Central Adminis-
tration of Statistics in 2007, taking into account gender, age, 
and dwelling region.10 Cluster effect was taken into account, 
according to Rumeau-Rouquette and collaborators.17
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COPD was defined and classified according to the Global 
Initiative for Chronic Obstructive Lung Disease (GOLD) 
guidelines,1 and according to the LLN (FEV1/FVC post-
bronchodilator below the fifth percentile of the healthy 
population having the same age and gender of the individual 
would be considered to have COPD).7 The latter equations 
were calculated according to the method described by Cole 
and collaborators, separately for males and females,18 to 
predict the expected fifth percentile for every individual’s 
healthy population according to age and gender.
Significant reversibility was defined as an increase in 
post-bronchodilator FEV1 from baseline by 12% or more 
and by 200 mL or more.12
The chi-square test was used for cross tabulation of quali-
tative variables in bivariate analysis, and prevalence ratios 
(PRs) were calculated. Somers’ d-test was used to evaluate 
trends between ordinal variables.
A backward stepwise likelihood ratio logistic regression 
was performed for multivariate analysis: COPD was the 
dependent variable; sociodemographic characteristics (age, 
sex, marital status, working status, dwelling region, and 
education) and cigarette and water-pipe smoking were the 
independent variables. After ensuring model adequacy using 
the Hosmer–Lemeshow test, adjusted odds ratios (ORa) were 
calculated. Moreover, a stepwise descendant multiple linear 
regression analysis was performed to evaluate predictors of 
obstruction severity (percentage of FEV1 over-predicted) in 
ever-smokers. Sociodemographic data, cigarette and water-
pipe quantitative-related duration, and frequency of exposure 
were used as independent variables. Linearity of the relation-
ship, normality of residuals, and noncolinearity of retained 
variables were insured before the model was accepted.
Results
Sample description
Of the 3000 selected individuals aged 40 years and over, 
2201 individuals were interviewed and underwent two ade-
quate spirometric measurements (73.4%). After weighting, 
individuals were grouped into Lebanese regions as follows: 
361 in Beirut (16.4%), 882 in Mount Lebanon (40.1%), 
407 in North Lebanon (18.5%), 298 in South   Lebanon 
(13.6%), and 252 in the Bekaa Valley (11.5%). There were 
48.4% males and 51.6% females. Age groups were as 
  follows: 40–44 years (19.2%), 45–49 years (15.6%), 50–54 
years (14.3%), 55–59 years (13.3%), 60–64 years (12.4%), 
and .65 years (25.1%).
In this sample, 33.3% had never smoked, whereas 60% 
had ever smoked cigarettes, and 16.3% had ever smoked 
water-pipe. For current-smokers, 33.2% smoked cigarettes, 
6% smoked water-pipe, and 4.2% were current mixed-
smokers. For previous-smokers, 20.4% smoked cigarettes, 
3.1% smoked water-pipe, and 3.6% were previous mixed-
smokers. Of the “ever” cigarette smokers, 15.9% were also 
“ever” water-pipe smokers; of the “ever” water-pipe smokers, 
58.5% had ever smoked cigarettes.
COPD prevalence and staging
Among 2201 individuals, the prevalence of COPD was 
9.7% (95% CI: 8.5%–10.9%), according to the GOLD 
definition. Only 20.2% of these COPD patients had already 
been diagnosed and treated by a physician. Distribution of 
COPD stage in COPD patients was as follows: 17.6% mild 
(stage I), 58.3% moderate (stage II), 20.3% severe (stage III), 
and 3.8% very severe (stage IV). These figures translate 
into 1.7%, 5.6%, 2%, and 0.4% of the general population, 
respectively. Subsequent stage groups included 47.4%, 
37.9%, 25%, and 25% of females, respectively; they also 
included 86.5%, 89.6%, 95.3%, and 100% of ever-smokers, 
respectively.
According to the 5% LLN definition of COPD, the 
prevalence turned out to be 12.5% (95% CI: 11.2%–13.9%); 
4.1% of those aged less than 70 years, classified initially as 
non-COPD, were readjusted as COPD patients according to 
the LLN 5% definition. The opposite was the case for people 
aged over 70 years: 11.4% classified as COPD sufferers by 
the GOLD definition were found to be non-COPD by the 
LLN 5% definition (Figure 1).
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Figure 1 COPD prevalence according to GOLD guidelines (blue line) and lower 
limit of normal (green line).
Abbreviations: COPD, chronic obstructive pulmonary disease; GOLD, Global 
initiative for Chronic Obstructive Lung Disease.
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Among the COPD patients, 14% presented significant 
post-bronchodilator reversibility on spirometry; they rep-
resented individuals with a mixed disorder of asthma and 
COPD.
Of the entire sample, 50.2% had no chronic respiratory 
diseases or symptoms, with normal spirometry; whereas 
5.6% had significant post-bronchodilator reversibility on 
  spirometry, with clinical features suggestive of asthma, 
12.9% had restrictive pattern, and 22.1% had miscellaneous 
symptoms and abnormalities on spirometry.
respiratory symptoms
In this study’s COPD population, the most reported respira-
tory symptoms were: 52.7% chronic cough (95% CI: 46.8%–
58.5%), 59.6% sputum production (95% CI: 53.8%–65.3%), 
and 60.3% wheezing (95% CI: 54.6%–66.0%). As for dysp-
nea, the mean MRC score for these individuals was 2.36, the 
standard deviation was 2.07, and the median was 2.00. The 
25th percentile was 0, while the 75th percentile was 5.00.
No significant differences in symptoms across stages 
of COPD were found for chronic cough, sputum produc-
tion, and dyspnea at rest and on minor, moderate, or major 
effort. However, a significant trend of ascendance was found 
for nocturnal wheezing (7.9%, 11.2%, 25.6%, and 50%; 
P = 0.001) and post-viral wheezing (18.9%, 31.5%, 30.2%, 
and 75%; P = 0.045), reported in Figure 2A where symptoms 
are plotted by COPD stage.
A significant trend was also found across stages of COPD 
for a higher number of visits to the emergency department 
(ED) (P , 0.001) and to the doctor (P , 0.001) and a higher 
number of hospitalizations for more than 1 day due to exac-
erbations of respiratory problems (P , 0.001), represented 
in Figure 2B (plotted by COPD severity stage).
COPD bivariate analysis
In Table 1, COPD distribution is reported according to 
sociodemographic characteristics. There were significant 
differences between all subgroups: dwellers of the Bekaa 
Valley and Beirut, males, older age, not currently working, 
and widows or divorced were subgroups with a higher preva-
lence of COPD than the other subgroups. They also have a 
higher risk of cardiac diseases, and they may be more likely 
to have a low body mass index (BMI).
In Figure 3, the COPD prevalence by smoker subgroup 
is reported. It is noteworthy that the highest prevalence is 
found in mixed-smokers (31.1%; PR = 9.15), followed by 
cigarette smokers (16.5%; PR = 4.85), water-pipe   smokers 
(6.7%; PR = 1.97), and finally, never-smokers (3.4%; 
reference category). Moreover, a significant dose–effect 
relationship was found for both cigarettes and water-pipes: 
COPD prevalence increased from 5.2% in non-cigarette 
smokers to 7.3% in cumulative smokers of less than 15 
pack-years, 13.7% if cumulative smoking was between 15 
and 45 pack-years, and 34.3% if cumulative smoking was 
higher than 45 pack-years (P , 0.001 for trend). For cumu-
lative water-pipe smokers, COPD prevalence was 11.3% in 
non-water-pipe smokers, 11.6% in smokers of less than 15 
water-pipe-years, 18.2% if cumulative smoking was between 
15 and 40 water-pipe-years, and 37.2% if cumulative smok-
ing surpassed 40 water-pipe-years (P , 0.001 for trend).
Multivariate analysis
The multivariate analysis that was carried out for all individu-
als in this study is reported in Table 2: older individuals have 
an increased risk of COPD (ORa = 1.05); so do the “ever” 
cigarette smokers (ORa = 4.88) and the water-pipe smokers 
(ORa = 2.53). A borderline effect was found for the Bekaa 
region versus Beirut. All other sociodemographic character-
istics were removed from the model.
For nonsmokers, only older age (ORa = 1.23) and having 
a family history of chronic respiratory diseases (ORa = 2.96) 
were predictors of COPD. Gender, marital status, education, 
work status, dwelling district, and cardiac diseases did not 
significantly predict COPD in this group. Moreover, predic-
tors of obstruction severity in ever-smokers were: a higher 
age group, a higher cigarette-dependence score, and a longer 
duration of previous cigarette and water-pipe smoking. Other 
variables, particularly current smoking-related ones, did not 
predict obstruction severity (Table 2); whereas, in never-
smokers, only older age showed a significant prediction of 
obstruction severity (beta = −1.77).
Discussion
This is the first national study on COPD prevalence; it reveals 
a proportion of 9.7% of cases according to the GOLD defini-
tion in the adult Lebanese population aged 40 years and over. 
This prevalence rate is comparable to others reported in the 
literature and to European countries.15,16,19,20 There is a lack of 
comparative longitudinal studies, conducted locally, whereas 
Vasankari et al comparing prevalence of COPD throughout a 
decade found no increase in the prevalence trend in Finland,21 
and Soriano et al found an unexpected decrease in COPD 
prevalence in Spain.15 The Lebanese data from this present 
study will be available as a baseline tool for future studies of 
the impact on smoking-related diseases of the implemented 
ban on smoking in public places.
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It has for a long time been difficult to estimate COPD 
prevalence1,8 because of low awareness of the disease, 
under diagnosis, variability within age groups, and dis-
crepancies in the studies’ methodologies.9 Eighty percent 
of COPD patients in this present study’s population were 
not diagnosed, and this is comparable to other reported data 
worldwide.15,19 However, one of the main reasons for under 
recognition of this disease, for which mortality and mor-
bidity rates are increasing around the world, lies within its 
very own definition and diagnosis. A post-bronchodilator 
FEV1/FVC ratio of less than 70% in a spirometry test is 
still the basis of the diagnosis of COPD.1,12,22 In this present 
study, the special aspect of the performed spirometry was 
that both adrenergic and cholinergic pathways of bronchial 
obstruction23 were targeted by administering combined 
albuterol and ipratropium bromide inhaler (Combivent). 
This is not the routine procedure recommended in the 
guidelines;12 however, no real consensus and standardiza-
tion exists about the type of bronchodilator, the dose, and 
the time to wait before the post-bronchodilator test is to 
be performed.23
The method used in this present study allows hypo-
thetically full room for obstruction improvement during 
30 minutes before the post dose test;12,23 relying by that on 
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method, COPD is over-diagnosed in the higher age groups and 
under-diagnosed in younger age groups.4,6,7 The results of this 
present study were consistent with this statement.
Considering the GOLD stages classification, moderate 
(stage II) was the most prevalent (58.3%) in this present 
study’s population; this result was comparable to what 
is found in the literature.4,5,20 It is noteworthy that in this 
study there was also a consistent number of severe stages 
(20.3%). The symptoms recorded by the COPD patients in 
this study were mainly chronic cough, sputum production, 
and wheezing, whereas dyspnea was the major limiting 
symptom, especially for those complaining of breathless-
ness on minor effort (34.9%); these were consistent with 
other prevalence studies.2,5,15,16,25 The mean MRC score of 
2.36 in these individuals points out the significant impact 
of their disease on their quality of life.14,26,27 No signifi-
cant differences were found across the stages of COPD 
regarding sputum production, cough, and dyspnea. These 
results underline the poor predictive value for severity of 
the reported symptoms in COPD and is consistent with the 
literature;2,4,6 whereas the significant trend for more visits 
to the ED and to the doctor and higher number of hospi-
talizations for exacerbations across the stages of COPD is 
consistent with the results found in the Evaluation of COPD 
Longitudinally to Identify Predictive Surrogate End-points 
(ECLIPSE) study,5 where seriousness of the disease was 
unexpectedly reflected by the rate of exacerbations only. 
This finding may emphasize the need in the future to classify 
COPD more accurately by phenotypic clusters as suggested 
by Burgel et al.28
Males and older age, not currently working, and   widows 
or divorced were subgroups with higher prevalence of 
COPD than the others, and that was comparable to other 
data in the literature.16,25,28 These subgroups had a higher 
risk of cardiac disease, which is also a known comorbidity 
in COPD, the only retained criteria in the bivariate analy-
sis being similar to what is found in the literature.28,29 It is 
of note that the presence of cardiac disease may by itself 
overestimate COPD prevalence, since congestive heart dis-
ease may show airflow congestion by lung congestion. But 
in Lebanon, the answer about the presence of any cardiac 
diseases with the questioned individual would mean in the 
majority of the cases – if positive – ischemic heart diseases. 
This issue remains to be discussed in other specifically 
designed studies.
Living in the Bekaa Valley and the capital Beirut were inde-
pendent risk factors of COPD; environmental measurements of 
Table 1 COPD distribution according to sociodemographic and 
disease characteristics
Characteristic No COPD 
(n = 1917)
COPD 
(n = 284)
95% CI Total 
(n = 2201)
Region
Beirut 83.7% 16.3% 12.4–20.0 361
Mount Lebanon 88.4% 11.6% 9.4–13.7 882
north Lebanon 88.9% 11.1% 8.1–14.2 406
South Lebanon 89.9% 10.1% 6.7–13.5 298
Bekaa plain 81.0% 19.0% 14.0–23.8 253
Gender
Male 84.8% 15.2% 13.1–17.4 1065
Female 89.3% 10.7% 8.9–12.5 1133
Age group
40–54 years 93.5% 6.5% 5.0–7.9 1081
55–69 years 82.1% 17.9% 15.1–20.6 738
$70 years 78.5% 21.5% 17.4–25.7 382
Education
illiterate 89.0% 11.0% 5.9–16.2 146
,8 years of school 85.1% 14.9% 11.5–18.2 430
8–12 years of school 82.9% 17.1% 13.6–20.5 463
12.1–15.0 years  
of school
83.9% 16.1% 13.1–19.1 573
University studies 94.3% 5.7% 3.8–7.6 566
Work status
Currently working 90.2% 9.8% 8.1–11.6 1127
retired 77.5% 22.5% 17.9–27.0 320
Unable to find work 88.5% 11.5% 1.0–26.7 26
never work 86.5% 13.5% 11.0–15.9 726
Marital status
Married 87.2% 12.8% 11.2–14.3 1786
Single 90.6% 9.4% 5.3–13.1 213
Widowed or  
divorced
81.0% 19.0% 13.4–25.0 179
Body mass index
normal weight 86.0% 14.0% 11.6–16.6 748
Overweight 87.4% 12.6% 10.5–14.7 945
Obesity 88.2% 11.8% 8.9–14.6 493
Cardiac problem
no 88.2% 11.8% 10.3–13.3 1828
Yes 81.7% 18.3% 14.3–22.2 68
Abbreviations:  CI,  confidence  interval;  COPD,  chronic  obstructive  pulmonary 
disease.
the different peak effect of the two components (albuterol 
and ipratropium) of the bronchodilator used. However, this 
could have lead to an underestimation of COPD prevalence 
in the study population by a better classification based on the 
significant reversibility criteria into (1) mixed obstructive 
disease due to COPD and asthma or (2) pure asthma.
However, the emerging new concept that COPD is an 
accelerated process of lung aging24 has raised many questions 
about the limitation of the fixed ratio in diagnosing COPD.3–6 
Many have suggested relying on the value of the 5% LLN of 
FEV1 for the diagnosis of COPD.6,7 It is clear that, by the   former 
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regional noxious pollutant concentrations are needed to further 
explain this finding.
On the other hand, smoking has been identified as the main 
cause of COPD.1 In this present study, there were no other 
exclusion criteria than being under 40 years old. By looking 
at the smoking status of the 2201 people included, only 33.3% 
had never smoked. Consequently, the highest prevalence 
for COPD was found in mixed-smokers (31.1%), compared 
with 3.4% of COPD in never-smokers. The multivariate 
analysis results were concordant with other epidemiological 
studies,2,3,5,16,25 with one particular finding neither clearly nor 
frequently reported elsewhere in literature:30 the link between 
water-pipe smoking and COPD. That finding is consistent 
with other previously demonstrated associations between 
water-pipe smoking and chronic respiratory symptoms.31
The 3.4% of patients who were nonsmokers with COPD 
showed in the multivariate analysis the same risk factors as 
in other studies such as the aging process,24 previous his-
tory of respiratory diseases in the family and acquisition of 
COPD in early life,19,25,32 and also environmental exposure 
such as wood smoke and passive smoking.16,32 Unlike other 
reports in the literature, low BMI was not correlated with 
COPD,3,19,32 and obesity was found to be correlated with 
restrictive patterns;2 the nonsignificant trend found in this 
present study could be explained by a low power of the study 
to detect BMI difference or by the subjective nature of weight 
and height reporting in this study.
The present study may be subject to several biases: 
a selection bias is possible due to the nature of the selected 
sample. Although a weighting procedure was used to make 
the sample as representative of the general population 
in Lebanon as possible, there was still a possibility of a 
selection bias because there was no means to evaluate the 
reasons of refusal, which could have lead to an overesti-
mation or underestimation of the COPD prevalence. The 
authors of this study guess that refusals were linked to 
nonmotivation, illiteracy, or maybe due to chronic diseases 
that individuals did not want to disclose (cancer or other 
diseases). However, the low refusal rate obtained makes 
this issue of minor importance. There is also a possibil-
ity of an information bias in this study: as in all studies 
involving questionnaires, relying on individuals reporting 
for several variables may include a recall bias (for previ-
ous smoking data for example) or subjectivity bias (for 
weight, height, symptoms reporting, and other reported 
information in the questionnaire). Moreover, the portable 
spirometer used may not be as sensitive and specific as 
the ones that are used in hospitals, which may introduce 
a classification bias. However, the methods used in the 
study are the ones that are currently being used all over 
the world for this kind of study; in the future, improved 
methods may help to fine tune the results of this particular 
study, but the authors believe that changes will not be of 
major importance.
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Conclusion
In this first epidemiological study in Lebanon about COPD, 
a high prevalence of the disease was determined, 80% of 
which was undiagnosed by a physician. Older individuals 
have an increased risk of COPD, in addition to “ever” ciga-
rette smokers and water-pipe smokers. Older age, duration 
and frequency of cigarette smoking, and duration of previous 
water-pipe smoking correlated with severity of obstruction. 
Awareness must be raised about COPD in Lebanon, and diag-
nosis must be improved. Treatment and prevention programs, 
added to smoking-cessation programs tackling the unmasked 
risk of water-pipe smoking,33 must be implemented to reduce 
prevalence, morbidity, and mortality from COPD.
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